NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Geron Corporation (NASDAQ: GERN) between February 28, 2024 and February 25, 2025, both dates inclusive (the “Class Period”), of the important May 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased Geron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Geron Corporation securities between February 28, 2024, and February 25, 2025, of the May 12, 2025, deadline to serve as lead plaintiff in a class action lawsuit [1][2] Group 1: Class Action Details - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by May 12, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that Geron made false and misleading statements regarding the launch and profitability of its drug RYTELO, impacting investors' financial prospects [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and recognition in the field [3]

Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified class period from February 28, 2024, to February 25, 2025 [1][2]. Allegations Against Defendants - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [2]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions and competition [2]. - RYTELO reportedly lacked market awareness, hindering Geron's ability to meet the unmet need for the drug among first-line patients and those outside academic settings [2]. - Statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [2]. Lead Plaintiff Process - Investors in Geron have until May 12, 2025, to seek appointment as a lead plaintiff representative for the class, or they may choose to remain absent class members [3]. - The lead plaintiff will represent all class members in directing the litigation and will select counsel to represent the class [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].